Compounds > moxifloxacin
Page last updated: 2024-09-04

moxifloxacin and Pneumococcal Infections

moxifloxacin has been researched along with Pneumococcal Infections in 55 studies

Research

Studies (55)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (5.45)18.2507
2000's34 (61.82)29.6817
2010's15 (27.27)24.3611
2020's3 (5.45)2.80

Authors

AuthorsStudies
Appelbaum, PC; Credito, KL; DeWasse, B; Kosowska-Shick, K; McGhee, P; Pankuch, GA1
Klugman, KP; Levin, BR; McGee, L; Rozen, DE1
Kaatz, GW; LaPlante, KL; Lodise, TP; Rybak, MJ; Tsuji, B1
Chang, CL; Jeong, J; Jeong, SH; Jung, HJ; Kim, HR; Kim, S; Lee, EY; Lee, JN; Shin, JH1
Ardanuy, C; Bouza, E; Calatayud, L; Cercenado, E; Fenoll, A; Liñares, J; Martín, R; Pallares, R1
Chang, KY; Ho, YH; Hsieh, YC; Hsueh, PR; Huang, LM; Huang, YC; Lin, HC1
Cai, L; Gilbert, GL; Kong, F; Oftadeh, S; Xiao, M; Xu, X; Zhou, F1
Bajaksouzian, S; Biek, D; Critchley, IA; Good, CE; Jacobs, MR; Jones, RN; Sader, HS; Windau, AR1
Bax, B; Brooks, G; Brown, BS; Brown, P; Cailleau, N; Chen, D; Dabbs, S; Davies, DT; Esken, JM; Giordano, I; Gwynn, MN; Hennessy, AJ; Hoover, JL; Jones, GE; Kusalakumari Sukmar, SK; Markwell, RE; Miles, TJ; Minthorn, EA; Pearson, ND; Rittenhouse, S1
Inagaki, H; Kitamura, T; Komoriya, S; Nagamochi, M; Odagiri, T; Takahashi, H1
Akpolat, N; Arabaci, C; Ay Altintop, Y; Aydemir, SS; Aydin, F; Bayramoglu, G; Birinci, A; Cekin, Y; Ceyhan, M; Gulay, Z; Gultekin, M; Gurler, N; Hascelik, G; Ozakin, C; Ozhak Baysan, B; Ozturk, C; Sanal, L; Sancak, B; Soyletir, G; Yaman, A; Zer, Y1
Chai, X; Sun, H; Wei, S; Xu, G1
Chen, HC; Chen, KJ; Chen, YP; Chong, YJ; Kang, EY; Lai, CC; Liu, L; Sun, MH; Wu, WC1
Noreddin, AM; Salem, AH1
Drobot, EI; Kondrashova, NM; Lyapun, IN; Plekhova, NG; Somova, LM1
Muccioli, GG; Tulkens, PM; Van Bambeke, F; Vandevelde, NM1
Adebambo, B; Senthilvel, E; Shah, C1
Hesje, CK; Marquart, ME; Moore, Q; Norcross, EW; Sanders, ME; Sanfilippo, CM; Shafiee, A1
Baba, S; Fujisawa, T; Harabuchi, Y; Ikeda, F; Kobayashi, T; Kurono, Y; Nishimura, T; Suzuki, K; Ubukata, K; Yamanaka, N1
Green, K; Low, DE; McGeer, A; Melano, R; Patel, SN; Pillai, DR; Tyrrell, GJ1
Bartell, J; Cupp, G; Garber, R; Stroman, D; Tauber, S; Vohra, F1
Gomez-Gutierrez, P; Lupala, CS; Perez, JJ1
Acharya, NR; Greninger, DA; Keenan, JD; Lietman, TM; Mascarenhas, J; McClintic, SM; Srinivasan, M1
Acharya, NR; Geetha, M; Glidden, D; Karpagam, R; Lietman, TM; McLeod, SD; Oldenburg, CE; Prajna, L; Ray, KJ; Srinivasan, M; Sun, CQ1
Bowker, KE; Holt, HA; MacGowan, AP; Rogers, CA1
Fridman, E; Lev, A; Levi, I; Rubinstein, E; Strahilevitz, J1
Bello, S; Torres, A1
Ariano, RE; Harding, GK; Iacovides, H; Sun, S; Zelenitsky, SA1
Dower, SK; Moore, LJ; Pridmore, AC; Read, RC1
Garrison, MW; Madaras-Kelly, KJ; Schimmels, JA1
Choudhri, S; Cihon, C; Herrington, J; Johnson, P1
Charles, PE; Chavanet, P; Croisier, D; Drlica, K; Etienne, M; Lequeu, C; Piroth, L; Portier, H1
Crawford, SA; Jorgensen, JH; McElmeel, LM; Whitney, CG1
Aguilar, L; Alkorta, M; Giménez, MJ; Pérez-Trallero, E; Vicente, D1
Charles, PE; Chavanet, P; Croisier, D; Etienne, M; Lequeu, C; Piroth, L; Portier, H; Pugin, J1
Alou, L; del Carmen Ponte, M; Gracia, M; Huelves, L; López-Casla, MT; Martínez-Marín, C; Prieto, J; Sevillano, D; Soriano, F1
Blair, C; Kirtsreesakul, V; Luxameechanporn, T; Naclerio, RM; Thompson, K1
Cars, O; Odenholt, I1
Adam, HJ; Baudry, TJ; Hoban, CJ; Hoban, DJ; Laing, NM; Nichol, KA; Schurek, KN; Zhanel, GG1
Amyes, SG; Dobay, O; Ghidán, A; Matuz, M; Nagy, K; Rozgonyi, F1
Mow, CS; Ochoa, RA1
Hoban, DJ; Noreddin, AM; Ostroski, M; Reese, AA; Zhanel, GG1
Dimopoulos, G; Falagas, ME; Giannopoulou, KP; Grammatikos, AP; Karageorgopoulos, DE1
Brück, W; Chen, V; Dalhoff, A; Kohlsdorfer, C; Nau, R; Schmidt, H; Schneider, O; Stuertz, K; Trostdorf, F1
Buxbaum, A; Georgopoulos, A; Graninger, W; Moser, C; Straschil, U1
Bianco, G; Capone, A; Cassone, M; Tarasi, A; Tarasi, D; Venditti, M1
Millichap, JJ; Noskin, GA; Pestova, E; Peterson, LR1
Bui, KQ; Mattoes, H; McNabb, J; Nicolau, DP; Nightingale, CH; Quintiliani, R; Xuan, D; Zhong, M1
George, RC; Johnson, AP; Livermore, DM; Warner, M1
Barzilai, A; Diamantstein, L; Gruzman, G; Keller, N; Rubinovitch, B; Rubinstein, E; Yoseph, G1
Black, J; Chartrand, SA; Moland, ES; Thomson, KS1
Jones, RN1
Rossi, C; Sternon, J1
Schentag, JJ1

Reviews

4 review(s) available for moxifloxacin and Pneumococcal Infections

ArticleYear
Efficacy and tolerability of moxifloxacin in the treatment of acute bacterial sinusitis caused by penicillin-resistant Streptococcus pneumoniae: a pooled analysis.
    Clinical therapeutics, 2004, Volume: 26, Issue:2

    Topics: Acute Disease; Adult; Aza Compounds; Drug Tolerance; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Penicillin Resistance; Pneumococcal Infections; Quinolines; Severity of Illness Index; Sinusitis; Streptococcus pneumoniae

2004
Deep infection of a total knee implant as a complication of disseminated pneumococcal sepsis. A case report and review of literature.
    The Knee, 2008, Volume: 15, Issue:2

    Topics: Anti-Infective Agents; Arthroplasty, Replacement, Knee; Aza Compounds; Fluoroquinolones; Humans; Knee Prosthesis; Male; Middle Aged; Moxifloxacin; Penicillins; Pneumococcal Infections; Prosthesis-Related Infections; Quinolines; Reoperation; Sepsis

2008
Fluoroquinolones compared with beta-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2008, Mar-25, Volume: 178, Issue:7

    Topics: Acute Disease; Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Fluoroquinolones; Humans; Moxifloxacin; Pneumococcal Infections; Quinolines; Randomized Controlled Trials as Topic; Sinusitis

2008
[Third and fourth generation fluoroquinolones].
    Revue medicale de Bruxelles, 2001, Volume: 22, Issue:5

    Topics: Administration, Oral; Anti-Infective Agents; Aza Compounds; Belgium; Biological Availability; Drug Monitoring; Drug Resistance; Fluoroquinolones; Gemifloxacin; Humans; Intestinal Absorption; Levofloxacin; Moxifloxacin; Naphthyridines; Ofloxacin; Patient Selection; Pneumococcal Infections; Quinolines; Respiratory Tract Infections; Streptococcus pneumoniae; Time Factors; Treatment Outcome

2001

Trials

2 trial(s) available for moxifloxacin and Pneumococcal Infections

ArticleYear
Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis.
    Advances in therapy, 2011, Volume: 28, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Child; Child, Preschool; Conjunctivitis, Bacterial; Double-Blind Method; Female; Fluoroquinolones; Haemophilus Infections; Haemophilus influenzae; Humans; Infant; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Pneumococcal Infections; Quinolines; Staphylococcal Infections; Staphylococcus aureus; Streptococcus pneumoniae; Young Adult

2011
Fluoroquinolone treatment and susceptibility of isolates from bacterial keratitis.
    JAMA ophthalmology, 2013, Volume: 131, Issue:3

    Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Bacteria; Corneal Ulcer; Double-Blind Method; Drug Resistance, Bacterial; Eye Infections, Bacterial; Female; Fluoroquinolones; Glucocorticoids; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Nocardia; Nocardia Infections; Pneumococcal Infections; Prednisolone; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Streptococcus pneumoniae

2013

Other Studies

49 other study(ies) available for moxifloxacin and Pneumococcal Infections

ArticleYear
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:2

    Topics: Amidohydrolases; Drug Resistance, Bacterial; Microbial Sensitivity Tests; Peptides; Pneumococcal Infections; Species Specificity; Streptococcus pneumoniae; Time Factors

2007
Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:2

    Topics: DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Pneumococcal Infections; Streptococcus pneumoniae; Transformation, Bacterial

2007
Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:4

    Topics: Area Under Curve; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae

2007
Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:7

    Topics: Anti-Bacterial Agents; Community-Acquired Infections; DNA, Bacterial; Drug Resistance, Bacterial; Erythromycin; Fluoroquinolones; Genes, Bacterial; Hospitals; Humans; Korea; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Molecular Epidemiology; Mutation; Ofloxacin; Pneumococcal Infections; Polymerase Chain Reaction; Prevalence; Reserpine; Respiratory Tract Infections; Retrospective Studies; Streptococcus pneumoniae

2007
Serotypes, Clones, and Mechanisms of Resistance of Erythromycin-Resistant Streptococcus pneumoniae Isolates Collected in Spain.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:9

    Topics: Anti-Bacterial Agents; Clone Cells; Drug Resistance, Multiple, Bacterial; Electrophoresis, Polyacrylamide Gel; Erythromycin; Genes, Bacterial; Microbial Sensitivity Tests; Phenotype; Pneumococcal Infections; Serotyping; Spain; Streptococcus pneumoniae; Tetracycline Resistance

2007
Clonal spread of highly beta-lactam-resistant Streptococcus pneumoniae isolates in Taiwan.
    Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:6

    Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Genotype; Humans; Microbial Sensitivity Tests; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae; Taiwan

2008
Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:3

    Topics: Anti-Bacterial Agents; Bacterial Proteins; Child, Preschool; DNA Transposable Elements; Drug Resistance, Bacterial; Erythromycin; Genotype; Humans; Macrolides; Microbial Sensitivity Tests; New South Wales; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae

2010
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:6

    Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Communicable Diseases, Emerging; Drug Resistance, Multiple, Bacterial; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae; United States

2010
Novel tricyclics (e.g., GSK945237) as potent inhibitors of bacterial type IIA topoisomerases.
    Bioorganic & medicinal chemistry letters, 2016, 05-15, Volume: 26, Issue:10

    Topics: Animals; Anti-Bacterial Agents; Chemistry Techniques, Synthetic; DNA Topoisomerases, Type II; Dogs; Drug Evaluation, Preclinical; ERG1 Potassium Channel; Gram-Negative Anaerobic Bacteria; Gram-Positive Bacteria; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; Pneumococcal Infections; Rats; Respiratory Tract Infections; Topoisomerase II Inhibitors

2016
Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
    Journal of medicinal chemistry, 2018, 08-23, Volume: 61, Issue:16

    Topics: Animals; Anti-Bacterial Agents; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; ERG1 Potassium Channel; Escherichia coli; Female; Humans; Macaca fascicularis; Male; Methicillin-Resistant Staphylococcus aureus; Mice, Inbred CBA; Microbial Sensitivity Tests; Pneumococcal Infections; Quinolines; Respiratory Tract Infections; Streptococcus pneumoniae

2018
Serotype distribution of
    Annals of medicine, 2023, Volume: 55, Issue:1

    Topics: Adolescent; Adult; Anti-Bacterial Agents; Cefotaxime; Erythromycin; Humans; Infant; Moxifloxacin; Penicillins; Pneumococcal Infections; Pneumococcal Vaccines; Serogroup; Streptococcus pneumoniae; Turkey

2023
The Formation and Drug Resistance Mechanism of Biofilm for Streptococcus pneumoniae Infection in Severe Respiratory Patients.
    Cellular and molecular biology (Noisy-le-Grand, France), 2023, Jan-31, Volume: 69, Issue:1

    Topics: Anti-Bacterial Agents; DNA Topoisomerase IV; Drug Resistance; Drug Resistance, Bacterial; Erythromycin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Penicillins; Pneumococcal Infections; Streptococcus pneumoniae

2023
Streptococcus pneumoniae endophthalmitis: clinical settings, antibiotic susceptibility, and visual outcomes.
    Scientific reports, 2021, 03-18, Volume: 11, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cataract; Cataract Extraction; Ceftriaxone; Cefuroxime; Corneal Ulcer; Endophthalmitis; Eye Enucleation; Eye Injuries; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Penicillins; Pneumococcal Infections; Retrospective Studies; Severity of Illness Index; Streptococcus pneumoniae; Taiwan; Tertiary Care Centers; Trabeculectomy; Treatment Outcome; Vancomycin; Vitrectomy

2021
Moxifloxacin in lower respiratory tract infections: in silico simulation of different bacterial resistance and drug exposure scenarios.
    Journal of chemotherapy (Florence, Italy), 2014, Volume: 26, Issue:2

    Topics: Area Under Curve; Bronchopneumonia; Ciprofloxacin; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Moxifloxacin; Pneumococcal Infections; Respiratory Tract Infections; Streptococcus pneumoniae

2014
Effects of immunomodulators on functional activity of innate immunity cells infected with Streptococcus pneumoniae.
    Bulletin of experimental biology and medicine, 2015, Volume: 158, Issue:4

    Topics: Animals; Bisbenzimidazole; Fluoroquinolones; Immunity, Innate; Immunologic Factors; Immunomodulation; Male; Mice; Moxifloxacin; Phagocytes; Pneumococcal Infections; Streptococcus pneumoniae

2015
Modulation of the activity of moxifloxacin and solithromycin in an in vitro pharmacodynamic model of Streptococcus pneumoniae naive and induced biofilms.
    The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:6

    Topics: Aged; Aged, 80 and over; Albuterol; Anti-Bacterial Agents; Biofilms; Bronchodilator Agents; Chromatography, High Pressure Liquid; Drug Interactions; Female; Fluoroquinolones; Humans; Ipratropium; Macrolides; Male; Mass Spectrometry; Microbial Viability; Middle Aged; Models, Theoretical; Moxifloxacin; N-Acetylneuraminic Acid; Pneumococcal Infections; Streptococcus pneumoniae; Triazoles

2015
Moxifloxacin: new indication. Inadequate restriction of indications in ENT and respiratory infections.
    Prescrire international, 2009, Volume: 18, Issue:103

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Bronchitis; Chemical and Drug Induced Liver Injury; Europe; Fluoroquinolones; Humans; Long QT Syndrome; Moxifloxacin; Pneumococcal Infections; Quinolines; Respiratory Tract Infections; Safety-Based Drug Withdrawals; Sinusitis; Stevens-Johnson Syndrome

2009
Red eye, blurry vision, and cough.
    The Journal of family practice, 2010, Volume: 59, Issue:4

    Topics: Anti-Infective Agents; Aortic Valve; Aortic Valve Insufficiency; Aza Compounds; Blindness; Ceftriaxone; Cough; Echocardiography, Transesophageal; Endophthalmitis; Fever; Fluoroquinolones; Hearing Loss, Sensorineural; Heart Valve Prosthesis; Humans; Male; Middle Aged; Mitral Valve; Moxifloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae; Vancomycin; Vision Disorders

2010
Comparative efficacy of besifloxacin and other fluoroquinolones in a prophylaxis model of penicillin-resistant Streptococcus pneumoniae rabbit endophthalmitis.
    Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2010, Volume: 26, Issue:3

    Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Colony Count, Microbial; Disease Models, Animal; Endophthalmitis; Fluoroquinolones; Gatifloxacin; Moxifloxacin; Ophthalmic Solutions; Penicillin Resistance; Pneumococcal Infections; Quinolines; Rabbits; Severity of Illness Index; Streptococcus pneumoniae; Time Factors

2010
[Mutant prevention concentrations of garenoxacin against Streptococcus pneumoniae isolates from otorhinolaryngological infections].
    The Japanese journal of antibiotics, 2010, Volume: 63, Issue:4

    Topics: Anti-Bacterial Agents; Aza Compounds; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Mutation; Ofloxacin; Otorhinolaryngologic Diseases; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae

2010
Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:8

    Topics: Anti-Bacterial Agents; Aza Compounds; Binding Sites; Canada; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae

2011
Molecular determinants of the bacterial resistance to fluoroquinolones: a computational study.
    Current computer-aided drug design, 2013, Volume: 9, Issue:2

    Topics: Acinetobacter; Acinetobacter Infections; Anti-Bacterial Agents; Aza Compounds; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Molecular Docking Simulation; Moxifloxacin; Pneumococcal Infections; Point Mutation; Quinolines; Streptococcus pneumoniae

2013
Improvement in corneal scarring following bacterial keratitis.
    Eye (London, England), 2013, Volume: 27, Issue:3

    Topics: Adult; Aged; Aza Compounds; Cicatrix; Corneal Ulcer; Eye Infections, Bacterial; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Pneumococcal Infections; Prednisolone; Pseudomonas Infections; Quinolines; Vision Disorders; Visual Acuity

2013
Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model.
    Antimicrobial agents and chemotherapy, 2003, Volume: 47, Issue:3

    Topics: Anti-Infective Agents; Area Under Curve; Aza Compounds; Colony Count, Microbial; Culture Media; Drug Resistance, Bacterial; Fluoroquinolones; Half-Life; Microbial Sensitivity Tests; Moxifloxacin; Pneumococcal Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Regression Analysis; Streptococcus pneumoniae

2003
Experimental pneumococcal pleural empyema model: the effect of moxifloxacin.
    The Journal of antimicrobial chemotherapy, 2003, Volume: 51, Issue:3

    Topics: Animals; Anti-Infective Agents; Aza Compounds; Disease Models, Animal; Empyema, Pleural; Fluoroquinolones; Male; Moxifloxacin; Pleura; Pneumococcal Infections; Quinolines; Rabbits; Turpentine

2003
[Pneumococcus and quinolone resistance].
    Archivos de bronconeumologia, 2003, Volume: 39, Issue:3

    Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Child, Preschool; Ciprofloxacin; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; Humans; Male; Microbial Sensitivity Tests; Moxifloxacin; Multivariate Analysis; Mutation; Ofloxacin; Penicillin Resistance; Penicillins; Pneumococcal Infections; Pneumonia, Pneumococcal; Quinolines; Recurrence; Risk Factors; Streptococcus pneumoniae

2003
AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model.
    The Journal of antimicrobial chemotherapy, 2003, Volume: 51, Issue:4

    Topics: Anti-Infective Agents; Area Under Curve; Aza Compounds; Culture Media; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Ofloxacin; Pneumococcal Infections; Predictive Value of Tests; Quinolines; Streptococcus pneumoniae

2003
Penicillin enhances the toll-like receptor 2-mediated proinflammatory activity of Streptococcus pneumoniae.
    The Journal of infectious diseases, 2003, Oct-01, Volume: 188, Issue:7

    Topics: Anti-Infective Agents; Aza Compounds; Choline; Colony Count, Microbial; Enzyme Inhibitors; Erythromycin; Ethanolamine; Fluoroquinolones; HeLa Cells; Humans; Interleukin-8; Membrane Glycoproteins; Moxifloxacin; N-Acetylmuramoyl-L-alanine Amidase; Penicillins; Pneumococcal Infections; Quinolines; Receptors, Cell Surface; Streptococcus pneumoniae; Toll-Like Receptor 2; Toll-Like Receptors; Transfection

2003
In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV.
    Diagnostic microbiology and infectious disease, 2003, Volume: 47, Issue:4

    Topics: Analysis of Variance; Aza Compounds; Culture Media; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Ofloxacin; Pharmacogenetics; Pneumococcal Infections; Probability; Quinolines; Reference Values; Regression Analysis; Sensitivity and Specificity; Streptococcus pneumoniae

2003
Effect of low-level resistance on subsequent enrichment of fluoroquinolone-resistant Streptococcus pneumoniae in rabbits.
    The Journal of infectious diseases, 2004, Oct-15, Volume: 190, Issue:8

    Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Lung; Moxifloxacin; Mutation; Pneumococcal Infections; Quinolines; Rabbits; Streptococcus pneumoniae

2004
Detection of resistance to gatifloxacin and moxifloxacin in Streptococcus pneumoniae with the VITEK 2 instrument.
    Journal of clinical microbiology, 2004, Volume: 42, Issue:12

    Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae

2004
In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
    International journal of antimicrobial agents, 2005, Volume: 25, Issue:2

    Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Models, Animal; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gemifloxacin; Levofloxacin; Mice; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumococcal Infections; Point Mutation; Quinolines; Sepsis; Streptococcus pneumoniae; Treatment Outcome

2005
The impact of mechanical ventilation on the moxifloxacin treatment of experimental pneumonia caused by Streptococcus pneumoniae.
    Critical care medicine, 2005, Volume: 33, Issue:5

    Topics: Animals; Area Under Curve; Aza Compounds; Community-Acquired Infections; Disease Models, Animal; Fluoroquinolones; Half-Life; Male; Moxifloxacin; Pneumococcal Infections; Quinolines; Rabbits; Respiration, Artificial

2005
Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones.
    International journal of antimicrobial agents, 2006, Volume: 27, Issue:4

    Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Male; Mice; Models, Biological; Moxifloxacin; Ofloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae; Survival Analysis

2006
The effect of treatment with moxifloxacin or azithromycin on acute bacterial rhinosinusitis in mice.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2006, Volume: 10, Issue:5

    Topics: Acute Disease; Animals; Anti-Bacterial Agents; Aza Compounds; Azithromycin; CD11b Antigen; CD4 Antigens; CD8 Antigens; Disease Models, Animal; Female; Fluoroquinolones; Male; Mice; Mice, Inbred C57BL; Moxifloxacin; Pneumococcal Infections; Quinolines; Rhinitis; Sinusitis; Streptococcus pneumoniae

2006
Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    The Journal of antimicrobial chemotherapy, 2006, Volume: 58, Issue:5

    Topics: Animals; Anti-Infective Agents; Area Under Curve; Aza Compounds; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Horses; Humans; Injections, Intravenous; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pneumococcal Infections; Quinolines; Staphylococcal Infections; Staphylococcus aureus; Streptococcus pneumoniae

2006
Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:1

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aza Compounds; Bacterial Proteins; Canada; Child; Child, Preschool; Ciprofloxacin; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Genotype; Humans; Infant; Infant, Newborn; Levofloxacin; Middle Aged; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumococcal Infections; Quinolines; Serotyping; Streptococcus pneumoniae

2007
The first steps towards fluoroquinolone resistance in Hungarian pneumococci.
    Journal of chemotherapy (Florence, Italy), 2006, Volume: 18, Issue:6

    Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Proteins; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Hungary; Microbial Sensitivity Tests; Moxifloxacin; Mutation, Missense; Ofloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae

2006
Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis.
    Clinical therapeutics, 2007, Volume: 29, Issue:12

    Topics: Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Community-Acquired Infections; Fluoroquinolones; Gemifloxacin; Humans; Monte Carlo Method; Moxifloxacin; Naphthyridines; Pneumococcal Infections; Quinolines; Respiratory Mucosa

2007
Moxifloxacin in the therapy of experimental pneumococcal meningitis.
    Antimicrobial agents and chemotherapy, 1998, Volume: 42, Issue:6

    Topics: Animals; Anti-Infective Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Fluoroquinolones; Meningitis, Pneumococcal; Moxifloxacin; Pneumococcal Infections; Quinolines; Quinolones; Rabbits; Streptococcus pneumoniae

1998
Comparative susceptibility to penicillin and quinolones of 1385 Streptococcus pneumoniae isolates. Austrian Bacterial Surveillance Network.
    The Journal of antimicrobial chemotherapy, 1999, Volume: 43 Suppl B

    Topics: Anti-Infective Agents; Austria; Aza Compounds; Drug Resistance, Microbial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Penicillin Resistance; Penicillins; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae

1999
Comparative in-vitro activity of moxifloxacin, penicillin, ceftriaxone and ciprofloxacin against pneumococci isolated from meningitis.
    The Journal of antimicrobial chemotherapy, 1999, Volume: 43, Issue:6

    Topics: Anti-Bacterial Agents; Aza Compounds; Ceftriaxone; Ciprofloxacin; Fluoroquinolones; Humans; Meningitis, Pneumococcal; Microbial Sensitivity Tests; Moxifloxacin; Penicillins; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae

1999
Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.
    The Journal of antimicrobial chemotherapy, 2000, Volume: 45, Issue:5

    Topics: Anti-Infective Agents; Aza Compounds; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance, Microbial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Pneumococcal Infections; Polymerase Chain Reaction; Quinolines; Reserpine; Sequence Analysis, DNA; Streptococcus pneumoniae

2000
Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
    Antimicrobial agents and chemotherapy, 2001, Volume: 45, Issue:3

    Topics: Animals; Anti-Infective Agents; Aza Compounds; Disease Models, Animal; Female; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Ofloxacin; Pneumococcal Infections; Quinolines; Rabbits; Streptococcus pneumoniae

2001
Activity of moxifloxacin against clinical isolates of Streptococcus pneumoniae from England and Wales.
    The Journal of antimicrobial chemotherapy, 2001, Volume: 47, Issue:4

    Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; England; Fluoroquinolones; Hospitals; Humans; Microbial Sensitivity Tests; Moxifloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae; Wales

2001
The effect of albumin, globulin, pus and dead bacteria in aerobic and anaerobic conditions on the antibacterial activity of moxifloxacin, trovafloxacin and ciprofloxacin against Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2000, Volume: 6, Issue:12

    Topics: Albumins; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Globulins; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Pneumococcal Infections; Quinolines; Staphylococcal Infections; Staphylococcus aureus; Streptococcus pneumoniae; Suppuration

2000
Activity of oral agents against pediatric isolates of Streptococcus pneumoniae.
    Diagnostic microbiology and infectious disease, 2001, Volume: 39, Issue:3

    Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Child; Child, Preschool; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Lactams; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae

2001
Conventional dogma applied to quinolones? Time for a change.
    The Journal of antimicrobial chemotherapy, 2001, Volume: 47, Issue:6

    Topics: 4-Quinolones; Anti-Infective Agents; Aza Compounds; Clinical Trials as Topic; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Outcome Assessment, Health Care; Pneumococcal Infections; Quinolines; Respiratory Tract Diseases; Streptococcus pneumoniae

2001
Pharmacokinetic and pharmacodynamic predictors of antimicrobial efficacy: moxifloxacin and Streptococcus pneumoniae.
    Journal of chemotherapy (Florence, Italy), 2002, Volume: 14 Suppl 2

    Topics: Anti-Infective Agents; Area Under Curve; Aza Compounds; Drug Resistance; Fluoroquinolones; Forecasting; Humans; Monte Carlo Method; Moxifloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae

2002